https://www.thebodypro.com/category/atripla-pro

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla)

The Latest

hole in a fence
News

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

Promo Image
News

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img
Conference Coverage

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Promo Image
News

This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

Promo Image
News

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

Promo Image
News

This Week in HIV Research: Check Your Frailty

The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.

Promo Image

This Week in HIV Research: Monday, Wednesday, Treatment Days

Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.

Atripla 3 Days a Week for 2 Years: Pilot Switch Study Reports Undetectable Viral Load With Better Bone, Kidneys and Sleep Img

Atripla 3 Days a Week for 2 Years: Pilot Switch Study Reports Undetectable Viral Load With Better Bone, Kidneys and Sleep

A small pilot study that switched people with undetectable viral load to reduced dosing for the Atripla reported no viral load rebounds with follow-up results out to two years.

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database Img
Conference Coverage

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database

Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds Img
News

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds

The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.